Notable exceptions include interferon (IFN)-α2b (also known as Intron A®), and IL-2 (also known as aldesleukin and Proleukin®), which mediate single agent therapeutic activity in patients affected by melanoma, a tumor type particularly sensitive to immunotherapy [274, 284]. This evidence concerns the gene IL2 and melanoma.